Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immix Biopharma, Inc.IMMX · Entity 4958 | Director | May 22, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immix Biopharma, Inc.
Report date May 22, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 899,250 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 6,250 · Balance 899,250 F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2036-05-22 | Direct | 12,500 |
Reported balance
After 2026-05-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-22 · Grant · Acquired 12,500 · Balance 12,500 F4: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,915,913 |
Reported balance
Holding disclosure · report date 2026-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,915,913 F2: The Reporting Person is the sole member of VERITAS LIBERABIT VOS, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. The Reporting Person disclaims beneficial ownership of the securities held by VERITAS LIBERABIT VOS, LLC, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 50,000 |
Reported balance
Holding disclosure · report date 2026-05-22 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 50,000 F3: The Reporting Person is the sole member of Signature Collection Properties, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. The Reporting Person disclaims beneficial ownership of the securities held by Signature Collection Properties, LLC, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
F2: The Reporting Person is the sole member of VERITAS LIBERABIT VOS, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. The Reporting Person disclaims beneficial ownership of the securities held by VERITAS LIBERABIT VOS, LLC, except to the extent of his pecuniary interest therein.
F3: The Reporting Person is the sole member of Signature Collection Properties, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. The Reporting Person disclaims beneficial ownership of the securities held by Signature Collection Properties, LLC, except to the extent of his pecuniary interest therein.
F4: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001493152-26-026422 · ownership.xml · derivative · entry 4 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-22 F4 · derivative.exercise_date: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. Read SEC document |
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-026422 · ownership.xml · nonDerivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,250 F1 · shares: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:57 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001641172-25-016112 · ownership.xml · derivative · entry 4 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-06-20 F3 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 21:20 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 40,000 | $2.19 | $87,680.00 |
DisclosureSEC source: 0001493152-24-052103 · ownership.xml · nonDerivative · entry 2 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 893,000 F2 · price: This transaction was executed in multiple trades at prices ranging from $2.147 to $2.25, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 21:20 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 7,700 | $2.17 | $16,678.20 |
DisclosureSEC source: 0001493152-24-052103 · ownership.xml · nonDerivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 853,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.11 to $2.21, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 20:45 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 8,100 | $2.25 | $18,233.10 |
DisclosureSEC source: 0001493152-24-033900 · ownership.xml · nonDerivative · entry 2 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 845,300 F2 · price: This transaction was executed in multiple trades at prices ranging from $2.162 to $2.29, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2024 Filed Aug 26, 2024 20:45 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 15,000 | $2.23 | $33,390.00 |
DisclosureSEC source: 0001493152-24-033900 · ownership.xml · nonDerivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,200 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.22 to $2.23, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 24, 2024 Filed Aug 1, 2024 01:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 6,000 | $2.15 | $12,877.20 |
DisclosureSEC source: 0001493152-24-029810 · ownership.xml · nonDerivative · entry 2 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822,200 F2 · price: This transaction was executed in multiple trades at prices ranging from $2.1191 to $2.166, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 18, 2024 Filed Aug 1, 2024 01:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 3,200 | $2.07 | $6,639.36 |
DisclosureSEC source: 0001493152-24-029810 · ownership.xml · nonDerivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 816,200 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.06 to $2.07576, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2024 Filed Jun 21, 2024 21:45 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001493152-24-024824 · ownership.xml · derivative · entry 4 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2034-06-11 F3 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 15, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 25,512 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001493152-24-020780 · ownership.xml · derivative · entry 5 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,512 Underlying: Common Stock · 25,512 shares Expires 2033-05-26 F3 · kind: Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024. F4 · derivative.exercise_date: The Stock Option will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 15, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 21,587 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001493152-24-020780 · ownership.xml · derivative · entry 4 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,587 Underlying: Common Stock · 21,587 shares Expires 2033-05-26 F3 · kind: Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 23:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 31,000 | $4.67 | $144,894.00 |
DisclosureSEC source: 0001493152-23-044618 · ownership.xml · nonDerivative · entry 2 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 813,000 F2 · price: This transaction was executed in multiple trades at prices ranging from $4.646 to $4.733, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 23:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 25,000 | $4.88 | $122,025.00 |
DisclosureSEC source: 0001493152-23-044618 · ownership.xml · nonDerivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 782,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.796 to $4.978, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 23:03 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 7,000 | $2.49 | $17,396.40 |
DisclosureSEC source: 0001493152-23-032969 · ownership.xml · nonDerivative · entry 4 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 757,000 F4 · price: This transaction was executed in multiple trades at prices ranging from $2.59 to $2.42, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 23:03 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 10,000 | $2.58 | $25,772.00 |
DisclosureSEC source: 0001493152-23-032969 · ownership.xml · nonDerivative · entry 3 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 F3 · price: This transaction was executed in multiple trades at prices ranging from $2.598 to $2.56, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2023 Filed Sep 18, 2023 23:03 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 30,000 | $2.83 | $84,864.00 |
DisclosureSEC source: 0001493152-23-032969 · ownership.xml · nonDerivative · entry 2 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 740,000 F2 · price: This transaction was executed in multiple trades at prices ranging from $2.91 to $2.70, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2023 Filed Sep 18, 2023 23:03 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 25,000 | $2.89 | $72,280.00 |
DisclosureSEC source: 0001493152-23-032969 · ownership.xml · nonDerivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 710,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.9299 to $2.83, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:58 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 10,000 | $2.53 | $25,317.00 |
DisclosureSEC source: 0001493152-23-032372 · ownership.xml · nonDerivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 685,000 F1 · price: This figure is the weighted average sales price of multiple trades ranging from $2.51 to $2.559 per share. The Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, Immix Biopharma, Inc. or any security holder of Immix Biopharma, Inc. full information about the number of shares sold at each separate price upon request. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 20:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001493152-23-028474 · ownership.xml · derivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-08-11 F1 · derivative.exercise_date: Options vest monthly over 12 months from the date of grant. Read SEC document |
| July 14, 2022 Filed Jul 18, 2022 10:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 16,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001493152-22-019501 · ownership.xml · derivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-07-14 F1 · derivative.exercise_date: Options vest monthly over 12 months from date of grant. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | ConversionConvertible Note · Derivative | Not disclosed | $0.00 Strike: $0.85 | $3,000,000.00 |
DisclosureSEC source: 0001493152-21-032039 · ownership.xml · derivative · entry 3 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common stock · 3,915,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On September 1, 2016, the Registrant issued VL a note in the amount of $3 million which is payable upon request of the majority holders of like tenure notes on or after March 31, 2022. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock. F3 · derivative.expiration_date: On September 1, 2016, the Registrant issued VL a note in the amount of $3 million which is payable upon request of the majority holders of like tenure notes on or after March 31, 2022. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock. F1 · ownership.nature: Jason Hsu is the Sole Member of VERITAS LIBERABIT VOS, LLC ("VL") and in such capacity has the right to vote and dispose of the securities held by such entity. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 50,000 | $5.00 | $250,000.00 |
DisclosureSEC source: 0001493152-21-032039 · ownership.xml · nonDerivative · entry 2 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 50,000 F2 · ownership.nature: Jason Hsu is the Sole Member of Signature Collection Properties, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | ConversionCommon Stock | 3,915,913 | $0.85 | $3,328,526.05 |
DisclosureSEC source: 0001493152-21-032039 · ownership.xml · nonDerivative · entry 1 Hsu Jason · CIK 0001895035 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,915,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Jason Hsu is the Sole Member of VERITAS LIBERABIT VOS, LLC ("VL") and in such capacity has the right to vote and dispose of the securities held by such entity. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.